ETOP 25-23 ADOPT-lung: An international, multicentre, open-label randomised phase III trial to evaluate the benefit of adding adjuvant durvalumab after neoadjuvant chemotherapy plus durvalumab in patients with stage IIB-IIIB (N2) resectable NSCLC.

Schmid, SabineSabineSchmidDimopoulou, GeorgiaGeorgiaDimopoulouvan Schil, PaulPaulvan SchilKönig, DavidDavidKönigMauti, LaetitiaLaetitiaMautiItchins, MalindaMalindaItchinsFrüh, MartinMartinFrühOselin, KerstiKerstiOselinLandi, LorenzaLorenzaLandiPérol, MauriceMauricePérolPopat, SanjaySanjayPopatAigner, ClemensClemensAignerForde, PatrickPatrickFordede Jong, Wouter KWouter Kde JongRoschitzki-Voser, HeidiHeidiRoschitzki-VoserGrolimund, EvaEvaGrolimundRuepp, BarbaraBarbaraRueppSolomon, BenjaminBenjaminSolomonFinn, StephenStephenFinnDafni, UraniaUraniaDafniStahel, RolfRolfStahelPeters, SolangeSolangePeters2025-07-092025-07-092025-06-23https://boris-portal.unibe.ch/handle/20.500.12422/212705en600 - Technology::610 - Medicine & healthETOP 25-23 ADOPT-lung: An international, multicentre, open-label randomised phase III trial to evaluate the benefit of adding adjuvant durvalumab after neoadjuvant chemotherapy plus durvalumab in patients with stage IIB-IIIB (N2) resectable NSCLC.article10.48620/8932140582281